Skip to main content
    E

    Erasca Inc (ERAS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.87
    +0.17 (+1.16%)

    Market Cap: $5.14B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    -17.54%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.14 - $-0.09
    8 analysts
    EPS RevisionsNo revisions (7d)
    2
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.12-5.4%
    60d ago$-0.12-5.4%
    30d ago$-0.12-7.6%
    7d ago$-0.13-2.7%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.59 - $-0.39
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 12
    		$-0.14$-0.12-16.67%Miss-16.7%
    Mar 26
    Reported May 11
    		$-0.60$-0.23-160.87%Miss-445.5%
    Dec 25
    Reported Mar 12
    		$-0.10$-0.11+8.26%Beat+9.1%
    Sep 25
    Reported Nov 12
    		$-0.11$-0.11+0.00%Beat+0.0%
    Jun 25
    Reported Aug 12
    		$-0.12$-0.11-9.09%Miss+58.6%
    Mar 25
    Reported May 13
    		$-0.11$-0.13+15.38%Beat+52.2%
    Dec 24
    Reported Mar 20
    		$-0.11$-0.13+15.38%Beat+45.0%
    Sep 24
    Reported Nov 12
    		$-0.11$-0.17+35.29%Beat+45.0%
    Jun 24
    Reported Aug 12
    		$-0.29$-0.19-52.63%Miss-38.1%
    Mar 24
    Reported May 8
    		$-0.23$-0.20-15.00%Miss-4.5%
    Dec 23
    Reported Mar 27
    		$-0.20$-0.23+13.04%Beat+81.1%
    Sep 23
    Reported Nov 9
    		$-0.20$-0.22+9.09%Beat+31.0%
    Jun 23
    Reported Aug 10
    		$-0.21$-0.24+12.50%Beat+30.0%
    Mar 23
    Reported May 15
    		$-0.22$-0.31+29.03%Beat+29.0%
    Dec 22
    Reported Mar 23
    		$-1.06$-0.32-231.25%Miss-307.7%
    Sep 22
    Reported Nov 9
    		$-0.29$-0.31+6.45%Beat+37.0%
    Jun 22
    Reported Aug 11
    		$-0.30$-0.33+9.09%Beat+75.0%
    Mar 22
    Reported May 12
    		$-0.31$-0.30-3.33%Miss+58.4%
    Dec 21
    Reported Mar 24
    		$-0.26$-0.34+23.53%Beat+61.5%
    Sep 21
    Reported Nov 10
    		$-0.46$-0.64+28.13%Beat+51.9%
    Jun 21
    Reported Jul 16
    		$-1.20$-0.65-84.62%Miss-
    Mar 21
    Reported Jun 2
    		$-0.74$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-0.68$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.96$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-15.65EV/EBITDAN/A
    Price/FCF-47.20xFCF Yield-2.12%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-78.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio8.29xQuick Ratio8.29x
    Trading Statistics
    Beta0.62Avg Volume5.56M
    52-Week High$24.2852-Week Low$2.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.92
    SMA 20$14.74
    SMA 50$16.29
    SMA 200$14.49
    EMA 10$14.93
    EMA 20$15.08
    EMA 50$15.77
    EMA 200$13.66

    MACD

    Line: -0.31Signal: -0.45Hist: 0.14

    ADX

    ADX: 16.3+DI: 17.6-DI: 20.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down40.0
    PSAR$14.29

    Bollinger Bands

    Upper Band$15.83
    Lower Band$13.65
    %B Position1480%(Upper)
    Band Width0.56

    RSI (14-Day)

    Neutral
    46.3

    Momentum Oscillators

    Stoch %K43.3
    Stoch %D55.5
    Williams %R-55.0
    ROC (10d)2.0%
    Momentum0.29
    CCI (20d)13.1
    MFI (14d)50.8

    Volatility Measures

    ATR (14d)$0.99(6.7%)
    StdDev (20d)0.55
    Hist Vol64.6%(High)

    Volume Flow

    VWAP$14.83
    OBV140.2M
    AD Line54.6M
    CMF (20d)-0.019

    Volume Metrics

    Avg Vol (20d)5.4M
    Vol Ratio1.6x(High)
    VWMA (20d)$14.82

    Pivot Points

    R3$15.88
    R2$15.48
    R1$15.09
    Pivot Point$14.69
    S1$14.30
    S2$13.90
    S3$13.51

    Advanced Oscillators

    TSI-10.82
    Ultimate Osc54.6
    KST-91.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$4.20M$0$0$0$5.58M$0
    Cost of Revenue$0$0$743,000$0$0$0$832,000$0$0$0$942,000$0
    Gross Profit$0$0$-743,000$0$0$0$-832,000$0$0$0$-942,000$0
    Operating Expenses$47.62M$187.91M$32.60M$34.55M$38.13M$35.63M$35.71M$37.24M$67.78M$38.85M$33.87M$34.66M
    R&D$35.90M$177.26M$23.24M$24.47M$28.67M$25.97M$26.12M$27.63M$55.53M$28.57M$24.80M$25.21M
    SG&A$11.72M$10.65M$9.36M$10.07M$9.46M$9.66M$9.59M$9.61M$12.25M$10.28M$9.07M$9.45M
    Operating Income$-47,619,000$-187,911,000$-32,604,000$-34,546,000$-38,125,000$-35,630,000$-35,712,000$-37,242,000$-67,782,000$-38,851,000$-33,872,000$-34,658,000
    Interest Income$3.60M$4.45M$3.57M$3.97M$4.33M$4.74M$5.28M$5.87M$5.04M$3.90M$4.24M$4.35M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-44,079,000$-183,440,000$-29,092,000$-30,612,000$-33,876,000$-30,966,000$-32,232,000$-31,200,000$-63,201,000$-35,017,000$-29,701,000$-30,361,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-44,079,000$-183,440,000$-29,092,000$-30,612,000$-33,876,000$-30,966,000$-32,232,000$-31,200,000$-63,201,000$-35,017,000$-29,701,000$-30,361,000
    EBITDA$-47,494,000$-187,912,000$-32,495,000$-34,850,000$-38,918,000$-36,870,000$-39,036,000$-38,745,000$-69,486,000$-40,261,000$-35,192,000$-36,136,000
    EBIT$-47,682,000$-187,889,000$-32,658,000$-34,583,000$-38,206,000$-35,706,000$-37,515,000$-37,069,000$-68,242,000$-38,917,000$-33,939,000$-34,707,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ERAS

    News

    An 8,333-share Erasca (ERAS) sale is proposed by Erasca Foundation, with shares valued at $122K.

    The Erasca Foundation has proposed selling 8,333 common shares of Erasca, Inc. (ERAS), valued at approximately $122,353. The sale is scheduled for October 15, 2026...

    Stock Titan•10/15/26•Neutral

    Form 144 Erasca For: 15 October By Investing.com

    This article from Investing.com is a straightforward notification regarding a Form 144 filing for Erasca, dated October 15. The content is brief, primarily serving as an alert for investors interested in ERAS...

    Investing.com Canada•10/15/26•Neutral

    Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

    Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Aardvark Therapeutics, Inc. (AARD), Coastal Financial Corporation (CCB), Erasca, Inc. (ERAS), and Power Solutions International...

    Carroll County Mirror-Democrat•10/15/26•Neutral

    Important Notice to Long-Term Shareholders of American Express Company (NYSE: AXP); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS) and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf

    Grabar Law Office is investigating claims on behalf of long-term shareholders of American Express Company (AXP), Coastal Financial Corporation (CCB), Erasca, Inc. (ERAS), and Planet Fitness...

    lincolnjournal.com•10/13/26•Bearish

    ERAS Stock Technical Analysis

    This article provides a technical analysis of Erasca Inc. Common Stock (ERAS), detailing its current stock price, market capitalization, trading volume...

    Pluang•10/10/26•Neutral

    ERAS Valuation and Fair Value

    P/E
    -15.7x
    P/FCF
    -47.2x
    P/B
    12.8x
    See GNG's fair value

    ERAS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -78.2%
    FCF yield
    -2.1%

    ERAS Competitors

    CompanyTicker
    Waystar Holding Corp. Common StockWAY
    Oruka Therapeutics, Inc.ORKA
    Mirum Pharmaceuticals IncMIRM
    Sotera Health CoSHC
    Merit Medical Systems IncMMSI
    PTC Therapeutics IncPTCT
    Teleflex IncorporatedTFX
    Travere Therapeutics IncTVTX

    Sector: Healthcare

    ERAS Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    2
    Buy
    6
    Hold
    2
    Sell
    0
    Strong Sell
    0

    ERAS Bull Case vs Bear Case

    Bull case

    • 80.0% of ERAS's analyst ratings are Buy or Strong Buy.

    ERAS Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -14.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 5 down

    Frequently Asked Questions About ERAS

    Does ERAS pay dividends?

    Erasca Inc (ERAS) does not currently pay a regular dividend.

    What is ERAS's market cap?

    Erasca Inc (ERAS) has a market capitalization of $5.14B with a current stock price of $14.87.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In